BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Monalizumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Monalizumab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05221840-2257@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:Monalizumab: Phase 3 readout est. (NCT05221840)
DESCRIPTION:Monalizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A G
 lobal Study to Assess the Effects of Durvalumab With Oleclumab or Durvalum
 ab With Monalizumab Following Concurrent Chemoradiation in Patients With S
 tage III Unresectable Non-Small Cell Lung Cancer\nEstimated primary comple
 tion: 8 January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /monalizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05221840
URL:https://assetmemo.bio/drug/monalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06503614-2257@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20271222
DTEND;VALUE=DATE:20271223
SUMMARY:Monalizumab: Phase 2 readout est. (NCT06503614)
DESCRIPTION:Monalizumab\, phase 2.\nStudy: A Trial of Durvalumab (MEDI4736)
  Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer\nEstimated primary
  completion: 22 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/monalizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06503614
URL:https://assetmemo.bio/drug/monalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07146230-2257@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Monalizumab: Phase 2 readout est. (NCT07146230)
DESCRIPTION:Monalizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The
  Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small
  Cell Lung Cancer Trial 2\nEstimated primary completion: April 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/monalizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07146230
URL:https://assetmemo.bio/drug/monalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769126-2257@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Monalizumab: Phase 2 readout est. (NCT06769126)
DESCRIPTION:Monalizumab\, phase 2.\nStudy: Using Biomarker Tests to Select 
 and Test New\, Personalized Treatments for Extensive Stage Small Cell Lung
  Cancer\, PRISM Study\nEstimated primary completion: 31 December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/monalizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06769126
URL:https://assetmemo.bio/drug/monalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05903092-2257@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Monalizumab: Phase 2 readout est. (NCT05903092)
DESCRIPTION:Monalizumab\, phase 2.\nStudy: MOnaliZumab in Combination With 
 durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer\nEstimated 
 primary completion: 31 October 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/monalizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05903092
URL:https://assetmemo.bio/drug/monalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-2257@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Monalizumab: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Monalizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer\n
 Estimated primary completion: 28 May 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/monalizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/monalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
